Retroscreen Virology Group, which creates drugs and vaccines for a number of viral respiratory diseases, has signed a Viral Challenge Model contract with a major global pharmaceutical company for the provision of a respiratory syncytial virus (RSV) challenge study.
The contract, valued at £5.9m, will be the largest RSV challenge study conducted by Retroscreen to-date.
Kym Denny, Chief Executive Officer, said: "We are delighted to be working with such an innovative pharmaceutical company on the development of their novel product.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
"This contract win comes from the building momentum of Retroscreen's sales pipeline and highlights the pharmaceutical industry's increasing awareness of the benefits of the VCM in accelerating drug development and product decision-making."
BoE: Millions of mortgage borrowers will be hit with higher repayments next year
News Higher interest rates are yet to fully hit households and monthly mortgage repayments will rise between £200 and £1,000 – how much will your home loan go up by?
By Marc Shoffman Published
Halifax: House prices rise for the second consecutive month
UK house prices rose again in November, suggesting a resilient property market amid economic turmoil in the past year- are we heading for a crash?
By Vaishali Varu Published